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Glioblastoma (GBM), a higher grade glial tumor, is highly aggressive, therapy resistant and often shows
poor patient prognosis due to frequent recurrence. These features of GBM are attributed to presence of a
signiﬁcantly smaller proportion of glioma stem cells (GSCs) that are endowed with self-renewal ability,
multi-potent nature and show resistance to therapy in patients. GSCs preferably take shelter close to
tumor vasculature due to paracrine need of soluble factors secreted by endothelial cells (ECs) of
vasculature. The physical proximity of GSCs to ECs creates a localized perivascular niche where mutual
GSC-EC interactions regulate GSC stemness, migration, therapy resistance, and cellular kinetics during
tumor growth. Together, perivascular niche presents a therapeutically targetable tumor structure for
clinical management of GBM. Thus, understanding cellular and non-cellular components in perivascular
niche is vital for designing in vitro and in vivo GBM tumor models. Here, we discuss the components and
structure of tumor vascular niche and its impact on tumor progression.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Glioblastoma (GBM) is an aggressive tumor of central nervous
system with overall median survival of 14 months. The high het-
erogeneity due to functionally diverse cell types, chaotic leakyscular Niche; ECs, Endothelial
anjali@nccs.res.in (A. Shiras).
Inc. This is an open access article uvasculature, and inﬁltrative nature of tumor cells contributes to
poor prognosis in patients [1]. As a standard therapy regime, GBM
patients undergo surgical de-bulking of tumor which is followed by
chemotherapy (Temozolomide or TMZ) along with radiation ther-
apy. Despite aggressive treatment 5 years patient survival in GBM is
below 5% due to rapid reoccurrence [2]. The causative agent for
reoccurrence in GBM is due to a rare subset of tumor cell clones
known as Glioma Stem Cells (GSCs) [3]. GSCs are undifferentiated,
multipotent, and self-renewing cell types which are functionally
characterized either via neurosphere formation assay in vitro [4] or
by limiting dilution assay for tumorigenicity in vivo Similar to adultnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Perivascular niche as GSC-EC interaction hub. Phenotypically diverse GSC populations anchor, migrate, and/or engage in active signaling within endothelial niche micro
environment.
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dependent on micro-environmental cues for maintaining their
phenotype and therefore, prefer to associate with auxiliary
microenvironment for their functionality and phenotype mainte-
nance [5].
Recent reports indicate that GSCs physically locate around blood
vessels for physiological or pathological purposes. Typically, blood
vessel endothelial cells create anatomical compartmentalization of
tumor regions known as perivascular niche (PN) [5e7]. PN is a
functional unit of cellecell interaction which maintains self
renewal, therapy resistance and growth properties of GSCs [8,9].
Interestingly, PN requirement is elaborated by multiple studies
demonstrating that GSCs undergo trans-differentiation and give
rise to functional ECs [10]. Similarly, trans-differentiation of GSCs
into ECs is a contributing factor in resistance to anti-angiogenic
therapy in glioblastoma [11]. Several studies are indicative that
treatment failure is GBM is due to 1) inherent tumor cell hetero-
geneity 2) presence of GSCs and PN like structures, and 3) invading
glioma cells which occupy surrounding brain parenchyma.2. Perivascular niche-components and soluble factors
Cellecell communication is vital not only for sensing the sur-
rounding microenvironment but also for cell fate determination. In
the chaotic cellular landscape of GBM it is pivotal for GSCs to
maintain their undifferentiated state. Predominantly, both physical
association and release of soluble factors via cellecell interactions
are augmented when interacting cells are in close proximity. For
GSCs, PN offers both. It helps in GSCs to adhere to vascular struc-
tures where they can physically interact with ECs (Fig. 1). Subse-
quently, PN allows access to increased localized concentrations of
soluble factors secreted by ECs [12,13], (Fig. 1). Interestingly, Cal-
abrese et al. showed that physical proximity of GSCs to ECs is a key
driver of tumor growth [5]. Using a mouse xenograft glioma model,they show that hierarchically organized mouse glioma tumors
decrease in size upon ablation of blood vessels. Thus, self-renewal
is represented as a function of number of endothelial cells in the
tumor. To functionally maintain self-renewal and stemness GSCs
require several autocrine and paracrine factors (e.g. soluble, non-
soluble) [14]. Many such factors are transcription factors, micro-
RNAs, or chromatin associated proteins and acts as cell autonomous
drivers of GSC cell fate by functioning in an autocrine manner [15].
However, other soluble factors such as ligands, cellular enzymes
and small hormone messengers are provided by ECs of PN and
function as paracrine modulators [13,16,17]. Due to the fact that
GSCs are key determinant of GBM aggressiveness and PN is a pos-
itive regulator of GSC functionality, many groups have recently
explored the underlying molecular mechanisms intersecting what
occurs inside PN compartment.2.1. Notch pathway
Notch signaling is one of the most studied stemness pathway
and appears to maintain self -renewal of GSCs [18,19]. GSCs pref-
erentially express Notch receptors Notch1 and Notch2 and show
activation of Notch signaling as evident by expression of target gene
Hes5 [20] Paracrine activation of GSC Notch receptors occurs via
two key Notch ligands Delta-like 4 (DLL4) and Jagged-1 that are
expressed on endothelial cells. In a mouse xenograft study, it was
found that when GSCs and ECs were co transplanted, EC speciﬁc
knock-down of Notch ligands caused decrease in tumor progres-
sion [21]. Similarly, Dll4 ligand is strongly expressed in tumor
endothelial cells and this promotes angiogenesis in an autocrine
manner [22]. Evidently, PN architecture is mutually beneﬁcial to
both GSCs as well as ECs as GSC promotes angiogenesis by allowing
proliferation of endothelial cells [23]. PN, therefore, becomes hub
for convergence of multiple cellular phenotypes (e.g. self renewal
maintenance, angiogenesis, cell proliferation).
Table 1
Autocrine and paracrine interaction between PN GSC-EC and involvement of multiple signaling pathways.
Soluble GSC self renewal factors Expression pattern Shown in perivascular niche
Tumor endothelial cell GSC
TGF-beta pathway
CD44/Id1 No Yes Yes
Nitric Oxide Yes No Yes
Cytokine pathway
Ligand- (IL-6) Yes No Yes
Receptors- CXCR1, CXCR2 No Yes
Notch pathway
Ligands-(JAGGD1, Dll4) Yes No Yes
Receptors- Notch1, Notch2 No Yes
Osteopontin (PN speciﬁc localization) Yes
ECM signaling
Receptor- Integrin a6 No Yes Yes
Ligand- Laminin e e
Sonic Hedgehog pathway
Ligand- SHH Yes No Yes/No
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TGF beta signaling is implicated in embryonic stem cell self-
renewal [24,25]. However, due to multiple novel downstream tar-
gets in cancer stem cells, the TGF-b pathway is involved in main-
taining cellular plasticity, Epithelial Mesenchymal Transition
(EMT), and therapy resistance [26]. TGF beta signaling promotes
self-renewal, inhibits differentiation and enhances oncogenic po-
tential of GSCs. This occurs through Smad induced JAK-STAT
pathway along with TGF-beta-Sox4-Sox2 driven signaling cascade
[26,27]. Further, convergence of TGF-beta and PDGFR signaling in
aggressive gliomas contributes to enhanced proliferation and
oncogenic potential of glioma stem cells [26]. In particular, peri-
vascular TGF-beta signaling is shown as therapy response predictor
in GBM. Anido et al. showed that TGF pathway inhibition targets
inhibitors of DNA-binding protein (Id)-1, and 3 in perivascular
GSCs [28]. Moreover, targeting a GSC subpopulation of CD44high/
Id1high cells derived from GBM patient inhibited tumor re-
occurrence in mouse xenograft model indicating a synergy be-
tween self-renewal and angiogenesis. Surprisingly, even though
perivascular ECs regulate GSC selferenewal, the role of TGF-beta
ligand in ECs that vitally comprise PN microenvironment is not
yet known.2.3. Nitric oxide (NO) pathway
Nitric oxide (NO) is one of the dual function molecules that
promote neural stem cell proliferation in a dose dependent manner
[29]. NO inhibition regulates stem and progenitor number in he-
matopoietic compartment [30]. Using a genetically engineered
mousemodel of PDGF driven glioma, Charles et al. showed that GSC
phenotype in perivascular niche is maintained by endothelial nitric
oxide (eNOS) [13]. Their study showed that eNOS induced paracrine
signaling in GSCs activates Notch pathway, increases neurosphere
formation, induces in vivo tumorigenicity, and thereby enhances
stem cell phenotype. In addition, functional studies revealed that
eNOS inhibition suppressed tumor formation resulting in increased
survival of tumor bearing mice. In another report, convergence of
PDGF-NOTCH-NO axis drives perivascular promotion of GSC
phenotype and angiogenesis simultaneously [31]. PDGF treatment
up-regulates stemness genes in patient derived neurosphere lines
via NO mediated inhibitor of differentiation-4 (ID4). In this multi-
lateral signaling study, PDGF treatment of glioma cells and endo-
thelial cells with ID4 caused JAGGED1 induction by inhibiting
microRNA-129. Together, the study shows simultaneous upregulation of stemness markers in GSCs and angiogenic phenotype
in endothelial cells, respectively. Importantly, even though in vivo
co-existence of GSCs-ECs is not incorporated in the experimental
design, co-convergence of multiple pathways proposes a much
more complex perivascular niche.2.4. Other pathways
Other pathways of GSC self-renewal include sonic hedgehog
(SHH), Wnt and integrin signaling [32,33]. SHH-Gli1 pathway
promotes GSC self-renewal and glioma growth. Although, tumor
endothelial cells speciﬁc SHH expression in genetically engineered
PDGF mouse tumors is known [32], paracrine activation of SHH-Gli
in GSCs is unexplored. Similarly, Wnt pathway is a stem cell speciﬁc
activator, however, its role in GBM perivascular niche is not well-
established. Additionally, extracellular matrix (ECM) signaling in
tumor microenvironment regulates multiple tumor cell functions.
In particular, ECM protein laminin regulates perivascular anchorage
of GSCs and self renewal through its cognate receptor integrin a6
on GSCs [12]. Therefore, Integrin a6 may assist in generation of
perivascular niche like structures in the tumor (Fig. 1) .3. Niche interaction model(s)-scope and pitfalls
The study of perivascular niche is relatively advanced in multi-
ple tumors due to its importance in understanding cancer stem cell
biology and tumor pathology. In GBM, since GSCs are not amenable
to inhibition by any known drugs and constitute therapy resistant
cell types, it is imperative to know how they achieve and maintain
such a state by locating themselves in PN microenvironment. This
will be most imperative for designing effective tumor growth
models and estimating therapy outcomes. To, extrapolate GSC
microenvironment of PN under in vitro conditions, non-physical
in vitro GSC-EC co-culture in a trans-well insert is often used. Other
options comprise use of human umbilical vein endothelial cells
(HUVEC) or other immortalized EC lines. Our search for existing
literature on PN related studies revealed that transwell insert
remained candidate choice for co-growing tumor cells with endo-
thelial cells for understanding molecular pathways in PN condi-
tions. As for any cellecell interaction induced effects to occur, not
only expression but also a deﬁned concentration of respective
signaling molecule is important for phenotype generation. In PN,
GSC-EC interactions occurs in a spatial-temporal manner in which
speciﬁed amount of signaling effectors, along with physical teth-
ering is required [33]. Since most of the GSC regulators (e.g. TGF-
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[34e36], they may exert differential effects according to existing
gradient. Similarly, in the highly heterogeneous tumor microenvi-
ronment optimum concentration of these molecules in PN micro-
environment is essential for obtaining a speciﬁc phenotype.
However, un-availability of a relevant co-culture system in addition
to non-availability of established tumor endothelial lines hinders
the development of a reﬁned, physical heterotypic GSC-EC inter-
action platform (Table 1).
4. Targeting niche-therapeutic opportunities
PN is shown to provide radio-resistance to CSC in a medullo-
blastoma mouse model [9]. Here, Hambardzumyan et al. showed
that enhanced Akt/PI3K activity in CSCs along with transient cell
cycle arrest increased their survival in PN microenvironment.
Moreover, Akt pathway inhibition occurred during radiation
induced apoptosis in CSCs. Similarly, PN speciﬁc Osteopontin-CD44
signaling axis radio-resistance in GSCs [16]. As during radiotherapy,
co-irradiation of GSCs and ECs occur in patient tumors. It was seen
that ECs up-regulated JAGGED1 expression upon radiation [37].
This is not only suggestive of enhanced GSC-EC interaction in PN
during radiation, but also indicates Notch1 as therapeutic target.
Notch inhibition either alone or synergistically with radiotherapy is
shown to kill GSCs [18,20].
5. Conclusion
PN is a vital assembly point of two clinically important tumor
cell types- GSCs and ECs. Even after 10 years of GSC identiﬁcation,
there is very little improvement in patient survival either due to
lack to GSC speciﬁc therapies or limitations GSC biology under
micro environmental conditions. GSCs generate GBM heterogene-
ity, promote angiogenesis, invade normal brain regions along tu-
mor vasculature and escape therapy [38e40]. All these therapy
impeding tumor features occur due to interactions with the sur-
rounding milieu. Hence, cellular, molecular, and functional char-
acterization of PN is crucial as it serves as a region of go-or-grow
regulator point for GSC phenotype maintenance. These studies may
help in determination of novel therapeutic opportunities for GBM
patients. It is interesting to study how ECs of PN are different from
ECs of non PN tumor vasculature. Also, during therapy, multiple
signaling pathways related to cell survival, apoptosis, migration,
cell cycle are activated and it would be important to study how they
incorporate and maintain diversity in dynamic pool of GSCs under
PN microenvironment [41e43]. Interestingly, most of these studies
related to PN analyze GSC phenotype maintenance; however,
regulation of PN ECs is not well studied. Lastly, as PN is preferred
region where GSCs reside, identiﬁcation of PN labeling molecules
for visualizing local niches may allow niche painting for both ther-
apeutic PN targeting and surgical removal of PN speciﬁc regions.
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